Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Heymach

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2022
In ResponseXiuning Le, John Heymach
The Lancet. Oncology|February 19, 2017
Consolidative local therapy in oligometastatic patients - Authors' replyDaniel Gomez, Stephen Swisher, John Heymach
Nature Medicine|September 2, 2003
Angiogenesis inhibitors and hypoxiaMark W Kieran, Judah Folkman, John Heymach
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|March 7, 2008
Dr. Folkman's legacy-a life of angiogenesis researchGeorge N Naumov, John Heymach, Lars A Akslen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2011
Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesisChristopher Lieu, John Heymach, Michael Overman, et al.
The Lancet. Oncology|September 16, 2015
SABR vs surgery for NSCLC in the mediaDavid Rice, Boris Sepesi, John Heymach, et al.
Cancer Research|February 27, 2009
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repressionKeyi Zhu, Waikin Chan, John Heymach, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged PopulationsEric K Singhi, Leora Horn, Lecia V Sequist, et al.
Clinical Lung Cancer|December 17, 2022
A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 AberrationsJohn Heymach, Frans Opdam, Minal Barve, et al.
Seminars in Oncology|July 9, 2019
Targeting angiogenesis for patients with unresectable malignant pleural mesotheliomaAnne Tsao, Takashi Nakano, Anna K Nowak, et al.
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2022
In ResponseXiuning Le, John Heymach
The Lancet. Oncology|February 19, 2017
Consolidative local therapy in oligometastatic patients - Authors' replyDaniel Gomez, Stephen Swisher, John Heymach
Nature Medicine|September 2, 2003
Angiogenesis inhibitors and hypoxiaMark W Kieran, Judah Folkman, John Heymach
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|March 7, 2008
Dr. Folkman's legacy-a life of angiogenesis researchGeorge N Naumov, John Heymach, Lars A Akslen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2011
Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesisChristopher Lieu, John Heymach, Michael Overman, et al.
The Lancet. Oncology|September 16, 2015
SABR vs surgery for NSCLC in the mediaDavid Rice, Boris Sepesi, John Heymach, et al.
Cancer Research|February 27, 2009
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repressionKeyi Zhu, Waikin Chan, John Heymach, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged PopulationsEric K Singhi, Leora Horn, Lecia V Sequist, et al.
Clinical Lung Cancer|December 17, 2022
A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 AberrationsJohn Heymach, Frans Opdam, Minal Barve, et al.
Seminars in Oncology|July 9, 2019
Targeting angiogenesis for patients with unresectable malignant pleural mesotheliomaAnne Tsao, Takashi Nakano, Anna K Nowak, et al.
Pageof 8